Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Patent allowance for BriaCell
December 2017
SHARING OPTIONS:

BERKELEY, Calif. & VANCOUVER—The U.S. Patent and Trademark Office and the European Patent Office have allowed two patent applications by BriaCell Therapeutics Corp. related to protein kinase C delta (PKCδ) inhibitor technology, titled “PKC Delta Inhibitors for Use as Therapeutics.” BriaCell also shared news of the advancement of its small-molecule program based on the proprietary PKCδ inhibitor technology, which was recently acquired from Sapientia Pharmaceuticals Incorporated. Members of the PKC family play a key regulatory role in a variety of cellular functions including cell growth and differentiation, gene expression, hormone secretion and membrane function.
 
“We are extremely pleased that both the U.S. Patent and Trademark Office and the European Patent Office have allowed these claims on PKC Delta Inhibitors for use as Therapeutics,” Dr. Douglas V. Faller, co-inventor of the patent and BriaCell’s scientific advisory board member, said in a press release. “This opens the door to the development of additional PKCδ inhibitors with better drug-like properties.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.